AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05169905 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: dTpa vaccine
Description: Single dose of the dTpa vaccine was planned to be administered intramuscularly, in the non-dominant arm, at Day 1 or at Day 31, depending on the vaccination schedule.~Two formulations of dTpa vaccine are licensed in the US and outside of the US (ex-US), respectively. dTpa-US formulation was administered to participants in centers located in the US, while dTpa-ex-US formulation was planned to be administered to participants in centers ex-US. The dTpa-ex-US formulation was not applicable in this study anymore as no non-US sites were initiated before the decision to stop the study.~The participants in RSV_dTpa-P and RSV_dTpa-A study groups were provided with an option to decide to receive dTpa vaccination as part of standard of care/local recommendation on immunization.~No vaccine was administered in the dTpa_RSV-P Group, since there were no participants assigned to it.
Study NCT06398587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onvansertib
Description: Given PO
Study NCT06398587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given IV
Study NCT06398587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Given IV
Study NCT04736589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamycin
Description: Oral 2mg, once a day.
Study NCT06657014 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mind-mindedness
Description: The Mind-Mindedness Training Intervention is a structured program designed specifically for primary caregivers of preschool-aged children (ages 4 to 7) who exhibit signs of social anxiety. This intervention is unique because it focuses on enhancing caregivers' understanding and responsiveness to their children's emotional and mental states through the concept of mind-mindedness.
Study NCT06657014 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: mind-mindedness
Description: The Mind-Mindedness Training Intervention is a structured program designed specifically for primary caregivers of preschool-aged children (ages 4 to 7) who exhibit signs of social anxiety. This intervention is unique because it focuses on enhancing caregivers' understanding and responsiveness to their children's emotional and mental states through the concept of mind-mindedness.
Study NCT06657495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD0015
Description: TD0015 is black, dark brown inside pilulae and has special smell of herbal, slightly sour then bitter taste.
Study NCT06657495 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TD0015 Placebo
Description: Placebo was packed in pack 5g
Study NCT06656832 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heart Failure network care
Description: Patients will receive three visits within the first three months after randomization for improving heart failure therapy at a cardiologist or the outpatient heart failure clinic
Study NCT06603883 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT) by nasal jejunal tube
Description: FMT was administered via a naso-jejunal tube to inject 50ml commercial intestinal bacterial suspension into the jejunum.
Study NCT06479603 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nintedanib
Description: The subjects will receive oral nintedanib. It will be prescribed to be taken after meals with 12 hrs gap between doses. The drug will be started at a dose of 100 mg twice daily. After 2 weeks, the dose will be titrated up to 150 mg twice daily, which will be continued till the end of 52 weeks. The standard-of-care immunosuppressive treatment will be continued along with the study drug (nintedanib). In case of intolerance to the 300 mg/day dose of nintedanib, the dose will be reduced to 100 mg twice daily. In case of severe adverse effects, the drug will be stopped and reintroduced after a period of up to 1-4 weeks. A dose of 100 mg twice daily will be started and continued. One attempt to titrate the dose up to 150 mg twice daily will be permitted.
Study NCT06479603 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: The subjects will receive the standard-of-care immunosuppressive treatment alone that may include glucocorticoids and other steroid-sparing agents that the subject would already be receiving.
Study NCT05591911 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Urine PCR testing
Description: The urine PCR panel will be performed to evaluate the bacterial growth in the patient's urine who is admitted with acute urinary tract symptoms.
Study NCT04695977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMP-001
Description: Subjects will receive CMP-001 10 mg IT weekly for 7 doses after which CMP-001 will be administered every 3 weeks (Q3W).
Study NCT04695977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 360 mg IV is administered Q3W.
Study NCT04839575 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latiglutenase
Description: Administered orally (daily)
Study NCT04839575 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally (daily)
Study NCT06398587 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrocardiography
Description: Undergo electrocardiography
Study NCT06398587 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT05040880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmione plus 80/12.5mg
Description: Test drug (Fixed-dose combination drug of telmisartan 80mg and hydrochlorothiazide 12.5mg)
Study NCT05040880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micardis plus 80/12.5mg
Description: Reference drug (Fixed-dose combination drug of telmisartan 80mg and hydrochlorothiazide 12.5mg)
Study NCT06398587 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET
Study NCT05992467 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wellness Enhancement for Caregivers (WECARE)
Description: WECARE behavioral intervention is guided by behavioral theories aimed to increase participants' caregiving mastery, enhance self-care, and improve psychosocial wellbeing. Participants will receive multimedia content on their WeChat account on cellphone or tablet, including short video clips, pictorial messages, short articles, and audio recordings 6 days a week, for 7 weeks.
Study NCT05428943 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: OPT101
Description: 15-mer peptide derived from the sequence of mouse CD154.
Study NCT06368869 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Livento press veneers luted with dual cured resin cement
Description: Veneers will be fabricated using Lithium disilicate (Livento® Press) ceramic and luted using Bifix QM dual cured cement
Study NCT06368869 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Livento press veneers luted with light cured resin cement
Description: Veneers will be fabricated using Lithium disilicate (Livento® Press) ceramic and luted using Bisco choice 2 light cured cement
Study NCT06368869 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Celtra duo veneers luted with dual cured resin cement
Description: Veneers will be fabricated using Zirconia-reinforced lithium silicate (Celtra® Press) ceramic and luted using Bifix QM dual cured cement
Study NCT06368869 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Celtra duo veneers luted with light cured resin cement
Description: Veneers will be fabricated using Zirconia-reinforced lithium silicate (Celtra® Press) ceramic and luted Bisco choice 2 light cured cement
Study NCT05807321 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fecobionics
Description: Fecobionics is a novel device to be inserted through the anal canal into rectum for studying defecation. Anorectal manometry and balloon expulsion test may be used as reference. Anorectal manometry and balloon expulsive test are standard methods for anorectal functional measurement.
Study NCT04721795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin with standard anti tuberculosis drugs
Description: Participants will receive oral 30/40mg of atorvastatin daily for 2 months together with oral doses of standard antituberculosis drugs consisting of Rifampicin, INH, Ethambuthol and pyrazinamide for 2months. At the end of 2months, participants will continue with only standard anti tuberculosis drugs, Rifampicin and INH for 4months.Doseage of antituberculosis drugs are dependent on weight
Study NCT04721795 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard anti tuberculosis drugs only
Description: Participants will receive oral doses of standard antituberculosis drugs consisting of Rifampicin, INH, Ethambuthol and pyrazinamide for 2months. At the end of 2months, participants will continue with only standard anti tuberculosis drugs, Rifampicin and INH for 4months.Doseage of antituberculosis drugs are dependent on weight
Study NCT06281340 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual therapy
Description: Each session will last approximately 50-60 minutes. Each session is composed of 10 techniques, 9 of which correspond to manual interventions commonly used in the field of manual therapy and adapted to patients with hemophilic arthropathy, according to the criteria previously established in studies that assess the safety of manual interventions in hemophilic arthropathy.
Study NCT06281340 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo manual therapy
Description: Each session will last approximately 50-60 minutes. Each session consists of the placebo application of 10 techniques, 9 of which correspond to manual interventions commonly used in the field of manual therapy and adapted to patients with hemophilic arthropathy, according to criteria previously established in studies that assess the safety of manual interventions in hemophilic arthropathy. In the techniques there will be no joint sliding, manipulations or myofascial inductions, being the only stimulus the contact of the physiotherapist with his hands and the pressure exerted with these, on the ankle.
Study NCT06398587 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT05132985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icotinib
Description: 125mg 1tt(Take 1 tablet 3 times a day) orally.
Study NCT05132985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75 mg/m2 (IV，Q3W)
Study NCT05132985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 5 (IV, Q3W)
Study NCT05132985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 mg/m2 (IV, Q3W)
Study NCT06398587 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo tumor biopsy
Study NCT06357221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetaphil
Description: Subjects will clean the skin with Cetaphil Gentle Skin Cleanser, and apply Cetaphil Moisturizing Cream to the lesion areas at least twice daily. Subjects will use Cetaphil Daily Facial Moisturizer SPF 35 as needed.
Study NCT05995704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apraglutide
Description: Peptide analogue of GLP-2
Study NCT05995704 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo to apraglutide
Study NCT05995704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Acetaminophen mixed with a liquid meal
Study NCT05995704 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acetaminophen
Description: Acetaminophen mixed with a liquid meal
Study NCT03652909 — intervention group
Intervention type: DEVICE
Intervention: Ascending Hearing Technologies device
Description: Personal Sound Amplification Device
Study NCT06117189 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Oral Health Impact Daily Life questionnaire including 7 domains (eating, speaking, appearance, social, psychological, health, and finance) and 16 questions regarding perceived intensity
Study NCT05233046 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition and Mental health counseling
Description: Nutrition and Mental health counseling with a standardized format included in each session
Study NCT05233046 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition and Mental health counseling with Nourish Carolina
Description: Nutrition and Mental health counseling with a standardized format included in each session combined with the intervention of a 12 week immersion of mindfulness based program ,Nourish Carolina, on CMS , school district employees. Nourish Carolina inlcudes, detailed lessons and descriptions with a caledar that includes mindful eating tips, activities, meditations recipes and videos. The program has monthly themes of mindfulness,gratitude and giving
Study NCT06378827 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine solution will be prepared by diluting one ampoule of dexmedetomidine (200µg/2ml) with 48 ml of saline solution to obtain a dexmedetomidine solution of 4µg/ml. Patients from the experimental group will receive a continuous infusion of dexmedetomidine at a dose of 0.5 µg/kg/h, until the end of the operation.
Study NCT06378827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine solution will be prepared by diluting one ampoule of dexmedetomidine (200µg/2ml) with 48 ml of saline solution to obtain a dexmedetomidine solution of 4µg/ml. Patients from the experimental group will receive a continuous infusion of dexmedetomidine at a dose of 0.5 µg/kg/h, until the end of the operation.
Study NCT05700461 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Implantable Microdevice (IMD)
Description: Small, implantable device with 20 microreservoirs for drug and drug combinations, via needle, percutaneously, and guided by interventional radiologic techniques.~Drugs include all or a subset of the following: Cabozantinib, Pazopanib, Lenvatinib, Axitinib, Ipilimumab, Nivolumab, Pembrolizumab, Carboplatin, Paclitaxel, Abemaciclib, Gemcitabine, Everolimus, Belzutifan, Cabozantinib + nivolumab, Cabozantinib + belzutifan, Ipilimumab + nivolumab, Lenvatinib + pembrolizumab, Lenvatinib + everolimus, Abemaciclib + belzutifan, and Tivozanib.
Study NCT06398587 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT05318365 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyethylene Glycol 3350
Description: PEG3350, klysma, laxoberal and magnesia will be administered in accordance with actual guidelines for treatment of constipation in children
Study NCT05318365 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Urotherapy
Description: Information and demystification of the disorder along with behavioural modification such as timed voiding, proper voiding posture, avoidance of holding manoeuvers and balanced fluid intake
Study NCT06376656 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive stimulation
Description: The cognitive stimulation will comprise of psychoeducation, videogaming, book club and technology training workshop sessions. Participants will take part in weekly sessions that are an hour long each.~For every six months, the participants will alternate between psychoeducation, videogaming, book club and technology training workshop sessions.
Study NCT06376656 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: The physical activity intervention will comprise of walking, Zumba, resistance exercise and aerobics sessions. Participants will take part in weekly sessions that are an hour long each.~For every six months, the participants will alternate between walking, Zumba, resistance exercise and aerobics sessions until the end of intervention period.
Study NCT04736589 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pyrotinib
Description: Oral 400mg, once a day.
Study NCT04736589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Chemotherapy drugs are not limited in this trial, please refer to their instructions for specific usage.
Study NCT04736589 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Chemotherapy drugs are not limited in this trial, please refer to their instructions for specific usage.
Study NCT04131374 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminiscence Therapy
Description: Virtual reality scenarios will be used to delivered reminiscence therapy with each caregiving dyad (i.e. person living with dementia; family member).
Study NCT05632874 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: relaxing breathing exercise
Description: Kumbhaka Pranayama, Sama Vritti Pranayama and box breathing breathing techniques will be applied to the patients.
Study NCT06144918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SBI-100 Ophthalmic Emulsion, 0.5%
Description: 0.5% (5 mg/mL) SBI-100 Ophthalmic Emulsion eyedrop
Study NCT06144918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SBI-100 Ophthalmic Emulsion, 1.0%
Description: 1.0% (10 mg/mL) SBI-100 Ophthalmic Emulsion eyedrop
Study NCT06144918 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SBI-100 Ophthalmic Emulsion, Placebo
Description: Placebo, SBI-100 Ophthalmic Emulsion eyedrop without the active ingredient (SBI-100)
Study NCT05632744 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CG-100 Intraluminal Bypass Device
Description: Subjects will be treated with the CG-100 Intraluminal Bypass Device
Study NCT05287360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivoceranib
Description: Rivoceranib will be supplied as film-coated tablets for oral administration as 4 different formulations: Formulation 1, 3, and 4 = 250 milligrams; Formulation 2 = 200 milligrams.
Study NCT06228755 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrative Medicine Group Visit
Description: Integrative Medicine Group Visit (IMGV) is a 9-week group visit series co-facilitated by a billing primary care provider and a trained co-facilitator (such as a behavioral health provider, mindfulness instructor, or yoga teacher). The IMGV will be delivered virtually over a secure telehealth platform for 2 hours weekly. The IMGV curriculum focuses on principles of mindfulness-based stress reduction, and includes patient education on pain, insomnia, nutrition, yoga, depression, self-massage, and self-acupressure.
Study NCT06228755 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Implementation Strategies
Description: Package includes:~* Patient strategies will include an orientation session to introduce patients to the IMGV model.~* Provider strategies include training in delivery of IMGV with continuing education credits. Training may be delivered on-line or in-person. Ongoing coaching in the first year of IMGV implementation will also be offered to providers leading IMGV, to increase self-efficacy to deliver the curriculum, and enhance fidelity.
Study NCT06221319 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sacral erectör spinae plane group
Description: sacral erectör spinae plane will be applied to patients in Group S
Study NCT05663983 — intervention group
Intervention type: BEHAVIORAL
Intervention: Description of therapeutical results
Description: Comparison between two groups of patients treated in different realities (Pediatric Hospital or Adult General Hospital)
Study NCT05047523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1840
Description: Administered as an oral tablet.
Study NCT06038630 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyperpolarized Xe129
Description: Hyperpolarized xenon will be administered in multiple doses in volumes up to 25% of subject TLC followed by a breath hold of up to 15 seconds.
Study NCT04334538 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: S-RUTF
Description: Children will receive approximately 175 kcal/kg/d of standard ready-to-use therapeutic food which provides a full daily doses of vitamins and micronutrients. Caregivers will instruct caregivers to feed the supplement only to the enrolled child.
Study NCT04334538 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: oat RUTF
Description: Children will receive approximately 175 kcal/kg/d of oat ready-to-use therapeutic food which provides a full daily doses of vitamins and micronutrients. Caregivers will instruct caregivers to feed the supplement only to the enrolled child.
Study NCT04719832 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK3511294 (Depemokimab)
Description: GSK3511294 (Depemokimab) will be administered using a pre-filled syringe.
Study NCT04719832 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be administered as a normal saline using a pre-filled syringe.
Study NCT05325710 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Study nurse intervention
Description: Contact everay 4 months with a dedicated study nurse
Study NCT05325710 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Study nurse intervention
Description: Contact everay 4 months with a dedicated study nurse
Study NCT06038630 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen Administration
Description: Oxygen administration